Thalidomide and irradiation combination therapy increases substance P levels in vitro

Şimşek Oz,Ece; Aydemir,Esra; Fidan Korcum,Aylin; Fıskın,Kayahan

doi:10.3892/etm.2011.216

Thalidomide and irradiation combination therapy increases substance P levels in vitro

Authors:
- Ece Şimşek Oz
- Esra Aydemir
- Aylin Fidan Korcum
- Kayahan Fıskın
View Affiliations

Affiliations: Department of Biology, Art and Science Faculty, Akdeniz University, 07058 Antalya, Turkey, Department of Radiation Oncology, Akdeniz University, 07058 Antalya, Turkey
Published online on: February 14, 2011 https://doi.org/10.3892/etm.2011.216
Pages: 529-535

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thalidomide is an anti-angiogenic agent that is used in the treatment of cancer. However, in many cases, particularly in patients with breast cancer, thalidomide treatment alone is insufficient and must be combined with other drugs or therapies. In the clinical setting, thalidomide is most commonly used in combination with radiation therapy. However, the exact mechanisms of its effect are unkown. Radiotherapy alters the expression of substance P, which is considered a crucial pro-angiogenic peptide. To determine whether thalidomide and radiotherapy in combination overcome the limitations of each as monotherapy, we examined the effects of the combination on the growth of breast cancer cells as well as on the expression of substance P in vitro. Mouse breast cancer cells (4T1) and cells produced from metastatic lesions (4THMpc) were treated with radiotherapy (RT) (45 Gy) alone, thalidomide (Thal) (40 µg/ml) alone or combination therapy (40 µg/ml Thal + 45 Gy RT), and compared with control cells. MTS, Live/Dead and trypan blue exclusion assays were used to evaluate the cytotoxic effects of the treatments. The levels of substance P in the conditioned media and in the cell lysates were determined by a substance P ELISA kit, and changes in the protein content were analyzed by Western blotting. Thalidomide alone resulted in a significant inhibition in the growth of the 4T1 (34.1%) and 4THMpc (52.6%) cell lines. RT alone inhibited the growth of the 4T1 (19.2%) and 4THMpc (23.31%) cell lines. The combination therapy enhanced the growth inhibition noted in the 4T1 (47.9%) and 4THMpc (62.03%) cell lines. The expression of substance P in the conditioned media and in the cell lysates increased within 72 h of RT. This increase was significantly enhanced with the combination therapy. These data indicate that thalidomide inhibits breast cancer cell growth and potentiates the anti-tumor effects of radiation at appropriate doses.

View Figures

View References

1.	Polyak K: On the birth of breast cancer. Biochim Biophys Acta. 1552:1–13. 2001.PubMed/NCBI
2.	Goss PE: Breast cancer prevention – clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol. 86:487–493. 2003.
3.	Dong X, Han ZC and Yang R: Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol. 62:105–118. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Schneider BP and Miller KD: Angiogenesis of breast cancer. J Clin Oncol. 23:1782–1790. 2005. View Article : Google Scholar : PubMed/NCBI
5.	Nishida N, Yaho H, Nishida T, Kamura T and Kojiro M: Angiogenesis in cancer. Vasc Health Risk Manag. 2:213–219. 2006. View Article : Google Scholar
6.	Pang R and Ronnie TP: Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 242:151–167. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Eichhorn ME, Kleespies A, Angele MK, et al: Angiogenesis in cancer: molecular mechanisms clinical impact. Langenbecks Arch Surg. 392:371–379. 2007. View Article : Google Scholar : PubMed/NCBI
8.	D’Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 91:4082–4085. 1994.
9.	Kenyon BM, Browne F and D’Amato RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 64:971–978. 1997. View Article : Google Scholar : PubMed/NCBI
10.	Bauer KS, Dixon SC and Figg WD: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is speciesdependent. Biochem Pharmacol. 55:1827–1834. 1998. View Article : Google Scholar : PubMed/NCBI
11.	Gasparini G, Longo R, Fanelli M, et al: Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol. 23:1295–1311. 2005. View Article : Google Scholar : PubMed/NCBI
12.	Adamowicz K, Marczewska M and Jassem J: Combining systemic therapies with radiation in breast cancer. Cancer Treat Rev. 35:409–416. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Nieder C, Wiedenmann N, Andratschke N, et al: Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev. 32:348–364. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Harrison L and Blackwell K: Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist. 9:31–40. 2004. View Article : Google Scholar : PubMed/NCBI
15.	Mravec B, Gidron Y and Hulin I: Neurobiology of cancer: interactions between nervous, endocrine and immune systems as a base for monitoring and modulating the tumorigenesis by the brain. Sem Cancer Biol. 18:150–163. 2008. View Article : Google Scholar : PubMed/NCBI
16.	Sumner SC, Gallagher KS, Davis DG, et al: Conformational analysis of the tachykinins in solution: substance P and physalaemin. J Biomol Struct Dyn. 8:687–707. 1990. View Article : Google Scholar : PubMed/NCBI
17.	Carter MS and Krause JE: Structure, expression and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K and neuropeptide gamma. J Neurosci. 10:2203–2214. 1990.
18.	Erin N and Ulusoy O: Differentiation of neuronal from nonneuronal Substance P. Regul Pept. 152:108–113. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Erin N and Clawson GA: Parameters affecting substance P measurement in heart, lung, and skin. Biotechniques. 37:232–239. 2004.PubMed/NCBI
20.	Singh D, Joshi DD, Hameed M, et al: Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis. Proc Natl Acad Sci USA. 97:388–393. 2000. View Article : Google Scholar : PubMed/NCBI
21.	Verheul HM, Pangigrahy D, Yuan J, et al: Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumor growth in rabbits. Br J Cancer. 79:114–118. 1999. View Article : Google Scholar : PubMed/NCBI
22.	Kotoh T, Dhar DK, Masunaga R, et al: Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery. 125:536–544. 1999. View Article : Google Scholar : PubMed/NCBI
23.	McMeekin DS, Sill MW, Benbrook D, et al: A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol. 105:508–516. 2007. View Article : Google Scholar : PubMed/NCBI
24.	Itasaka S, Komaki R, Herbst RS, et al: Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys. 67:870–878. 2007. View Article : Google Scholar : PubMed/NCBI
25.	Vala IS, Martins LR, Imaizumi N, et al: Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS One. 5:e112222010. View Article : Google Scholar : PubMed/NCBI
26.	Chan LW and Camphausen K: Angiogenic tumor markers, anti-angiogenic agents and radiation therapy. Expert Rev Anticancer Ther. 3:357–366. 2003. View Article : Google Scholar : PubMed/NCBI
27.	Esteban F, Gonzalez-Moles MA, Castro D, et al: Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology. 54:258–260. 2009. View Article : Google Scholar : PubMed/NCBI
28.	Aalto Y, Forsgren S, Kjörell U, Bergh J, Franzén L and Henriksson R: Enhanced expression of neuropeptides in human breast cancer cell lines following irradiation. Peptides. 19(2): 231–239. 1998. View Article : Google Scholar : PubMed/NCBI